Junguo Yin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Junguo Yin has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Dandan Gao
Department of Laboratory Medicine, First Hospital of Jilin University, Changchun, China
1 shared publication - Jiancheng Xu
Department of Laboratory Medicine, Infectious Diseases and Pathogen Biology Center, The First Hospital of Jilin University, China
1 shared publication - Panyang Xu
Department of Laboratory Medicine, First Hospital of Jilin University, Changchun, China
1 shared publication - Qi Zhou
Department of Pediatrics, First Hospital of Jilin University, Changchun, China
1 shared publication - Xuewen Li
Department of Laboratory Medicine, First Hospital of Jilin University, Changchun, China
1 shared publication - Yiting Wang
Department of Laboratory Medicine, First Hospital of Jilin University, Changchun, China
1 shared publication
Latest Publications
- Open Access
- 9 March 2022
- Published by Springer Nature in BMC Gastroenterology
- Vol. 22 (1) , 1-11
Early changes in laboratory tests predict liver function damage in patients with moderate coronavirus disease 2019: a retrospective multicenter study
Background: Most patients with coronavirus disease 2019 demonstrate liver function damage. In this study, the laboratory test data of patients with moderate coronavirus disease 2019 were used to establish and evaluate an early prediction model to assess the risk of liver function damage.Methods: Clinical data and the first laboratory examination results of 101 patients with moderate coronavirus disease 2019 were collected from four hospitals’ electronic medical record systems in Jilin Province, China. Data were randomly divided into training and validation sets. A logistic regression analysis was used to determine the independent factors related to liver function damage in patients in the training set to establish a prediction model. Model discrimination, calibration, and clinical usefulness were evaluated in the training and validation sets.Results: The logistic regression analysis showed that plateletcrit, retinol-binding protein, and carbon dioxide combining power could predict liver function damage (P < 0.05 for all). The receiver operating characteristic curve showed high model discrimination (training set area under the curve: 0.899, validation set area under the curve: 0.800;P < 0.05). The calibration curve showed a good fit (training set:P = 0.59, validation set:P = 0.19;P > 0.05). A decision curve analysis confirmed the clinical usefulness of this model.Conclusions: In this study, the combined model assesses liver function damage in patients with moderate coronavirus disease 2019 performed well. Thus, it may be helpful as a reference for clinical differentiation of liver function damage.Trial registrationretrospectively registered.
- 9 March 2022
- Published by Springer Nature in BMC Gastroenterology
- Vol. 22 (1) , 1-11
Open AccessEarly changes in laboratory tests predict liver function damage in patients with moderate coronavirus disease 2019: a retrospective multicenter study
Background: Most patients with coronavirus disease 2019 demonstrate liver function damage. In this study, the laboratory test data of patients with moderate coronavirus disease 2019 were used to establish and evaluate an early prediction model to assess the risk of liver function damage.Methods: Clinical data and the first laboratory examination results of 101 patients with moderate coronavirus disease 2019 were collected from four hospitals’ electronic medical record systems in Jilin Province, China. Data were randomly divided into training and validation sets. A logistic regression analysis was used to determine the independent factors related to liver function damage in patients in the training set to establish a prediction model. Model discrimination, calibration, and clinical usefulness were evaluated in the training and validation sets.Results: The logistic regression analysis showed that plateletcrit, retinol-binding protein, and carbon dioxide combining power could predict liver function damage (P < 0.05 for all). The receiver operating characteristic curve showed high model discrimination (training set area under the curve: 0.899, validation set area under the curve: 0.800;P < 0.05). The calibration curve showed a good fit (training set:P = 0.59, validation set:P = 0.19;P > 0.05). A decision curve analysis confirmed the clinical usefulness of this model.Conclusions: In this study, the combined model assesses liver function damage in patients with moderate coronavirus disease 2019 performed well. Thus, it may be helpful as a reference for clinical differentiation of liver function damage.Trial registrationretrospectively registered.